Peer-reviewed veterinary case report
Improved survival in dogs with aggressive hemangiosarcoma after chemo
By Finotello, R et al.·Published in Veterinary and comparative oncology·2017·Small Animal Teaching Hospital, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma.
- Species:
- dog
Plain-English summary
A 7-year-old Golden Retriever was diagnosed with a type of aggressive cancer called hemangiosarcoma after surgery to remove the tumor. The dog initially received a strong chemotherapy treatment called doxorubicin, followed by a gentler, continuous chemotherapy regimen. The results showed that dogs who received this combination treatment lived longer and had a better time before the cancer spread compared to those who only had the initial chemotherapy. The treatment was well tolerated, suggesting it could be a good option for dogs with this serious condition.
People also search for: dog hemangiosarcoma treatment · chemotherapy for dogs with cancer · Golden Retriever cancer survival rate
Abstract
Haemangiosarcoma (HSA) has an aggressive biological behaviour and carries a poor prognosis, with less than 10% of treated dogs surviving longer than 1 year. In this retrospective study a varied metronomic chemotherapy (MC) regimen preceded by adjuvant doxorubicin-based maximum-tolerated dose chemotherapy (MTDC) was compared with MTDC, in terms of efficacy [time to metastasis, (TTM) and survival time (ST)] and safety in dogs with biologically aggressive HSA. Dogs were eligible if they had no metastasis after MTDC and received either no further chemotherapy or MC maintenance. Twelve dogs received MTDC, and 10 received MC thereafter. Median TTM and ST were significantly longer for dogs receiving MTDC-MC (not reached versus 150 days, P = 0.028; and not reached versus 168 days, P = 0.030, respectively). Treatment was well tolerated. MTDC followed by MC is safe and suggests improved TTM and ST in dogs with surgically removed, biologically aggressive HSA that are treated in the microscopic setting.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26792231/